Table 3 CA125 and HE4 levels pre and post treatment for endometrial cancer
From: Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance
No reccurence (n = 72) | Recurrence (n = 26) | P value | |
|---|---|---|---|
Median CA125 (IQR) | |||
Diagnosis | 39 (20–79) | 85 (40–141) | 0.001a |
Interval | 11 (8–18) | 14 (11–36) | 0.033a |
Final | 12 (9–20) | 31 (14–90) | <0.001a |
Median HE4 (IQR) | |||
Diagnosis | 67 (47–117) | 132 (81–264) | <0.001a |
Interval | 58 (45–89) | 82 (64–119) | 0.003a |
Final | 57 (43–92) | 117 (82–197) | <0.001a |
HE4 at Diagnosis | |||
< 70 pmol/L | 41 (56) | 3 (12) | <0.001b |
>70 pmol/L | 32 (44) | 23 (88) | |
Interval HE4 | |||
<70 pmol/L | 49 (67) | 9 (35) | 0.004c |
>70 pmol/L | 24 (33) | 17 (65) | |
Final HE4 | |||
<70 pmol/L | 47 (64) | 5 (19) | <0.001c |
>70 pmol/L | 26 (36) | 21 (81) | |
CA125 at Diagnosis | |||
<35 U/ml | 35 (48) | 4 (15) | 0.005b |
>35 U/ml | 38 (52) | 22 (85) | |
Interval CA125 | |||
<35 U/ml | 69 (95) | 20 (77) | 0.019b |
>35 U/ml | 4 (5) | 6 (23) | |
Final CA125 | |||
<35 U/ml | 67 (91) | 14 (53) | <0.001c |
>35 U/ml | 6 (9) | 12 (47) | |